American Healthcare REIT vs Ventas
AHR and VTR side by side, both in miscellaneous investing. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AHR and VTR compare
Ventas is the larger company, worth 3.7 times as much as American Healthcare REIT ($46.6B against $12.6B).
On earnings, American Healthcare REIT is cheaper: it trades at 85.2× trailing earnings, against 166× for Ventas.
Ventas grew revenue faster over the last twelve months (22.1% versus 16.4% for American Healthcare REIT).
Both pay dividends: American Healthcare REIT yields 1.7% and Ventas 2.3%.
American Healthcare REIT scores higher on the StockData Score (11 against 6 for Ventas), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AHR | VTR |
|---|---|---|
| Size and price | ||
| Market cap | $12.6B | $46.6B |
| Share price | $57.94 | $88.04 |
| Change, 1 year | 19.9% | 12.9% |
| Change, 5 years | – | 77.9% |
| Beta (5Y) | 0.07 | −0.21 |
| Employees | 121 | 542 |
| StockData Score | ||
| Total score | 11 (better) | 6 |
| Valuation score | 0 | 0 |
| Growth score | 4 (better) | 3 |
| Performance score | 4 (better) | 0 |
| Health score | 2 | 2 |
| Dividend score | 1 | 1 |
| Valuation | ||
| P/E | 85.2× (better) | 166× |
| P/S | 5.0× (better) | 6.9× |
| P/B | 3.4× | 2.9× (better) |
| EV/EBITDA | 17.3× (better) | 19.0× |
| Fair value | $22.83 | $39.33 |
| Margin of safety | −154% | −124% (better) |
| Growth | ||
| Revenue growth (TTM) | 16.4% | 22.1% (better) |
| Revenue growth, 5Y average | 16.2% (better) | 9.0% |
| EPS growth (TTM) | – | 1.9% |
| EPS growth, 5Y average | 53.1% (better) | −14.3% |
| Profitability | ||
| Gross margin | 21.2% | – |
| Operating margin | 19.2% | – |
| Net margin | 4.8% | – |
| Return on equity | 4.0% | – |
| Return on invested capital | 16.5% | – |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Net debt / EBITDA | – | −0.08 |
| Interest coverage | 6.2× | – |
| Altman Z-score | 4.19 (better) | 1.81 |
| Piotroski F-score | 7 | – |
| Dividends and buybacks | ||
| Dividend yield | 1.7% | 2.3% (better) |
| Payout ratio | 148% | – |
| Years of dividend growth | 0 | 1 (better) |
| Dividend growth, 5Y average | 3.1% (better) | −2.2% |
| Buyback yield | −10.6% | −9.0% (better) |
| Shareholder yield | −8.9% | −6.7% (better) |
| Ownership | ||
| Held by institutions | 103% | 98.7% |
| Held by insiders | 0.63% | 0.45% |
| Insider net buying, 12 months | −$4.6M (better) | −$8.5M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 15.5% | 2.8% |
Go deeper
- AHR stock overview
- AHR income statement
- AHR valuation and score
- VTR stock overview
- VTR income statement
- VTR valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.